FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright

BioAtla, Inc. (NASDAQ:BCAB) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of BioAtla in a report released on Monday, March 31st. HC Wainwright analyst A. He anticipates that the company will post earnings per share of ($0.93) for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.46) per share.

BioAtla Trading Down 3.9 %

Shares of BCAB opened at $0.34 on Wednesday. The company has a market capitalization of $16.41 million, a PE ratio of -0.20 and a beta of 1.19. The business’s 50 day moving average is $0.40 and its 200 day moving average is $1.10. BioAtla has a 12-month low of $0.24 and a 12-month high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd increased its stake in BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after acquiring an additional 10,384 shares during the last quarter. Magnus Financial Group LLC purchased a new stake in shares of BioAtla during the 4th quarter valued at about $28,000. Two Sigma Investments LP grew its position in BioAtla by 84.0% in the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after acquiring an additional 61,725 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after purchasing an additional 100,204 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of BioAtla by 62.2% during the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after purchasing an additional 318,196 shares during the last quarter. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.